Plain-English translation of NCT05265299 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether aspirin can help people with chronic obstructive pulmonary disease (COPD), a condition that makes it hard to breathe. Researchers want to find the best dose of aspirin — whether a low, medium, or high amount — works most effectively for people with this lung disease. The study will measure how your body responds to each dose by looking at specific markers in your blood and urine.
COPD patients sometimes have problems with blood clotting and inflammation that may benefit from aspirin, but doctors aren't sure which dose would be safest and most helpful. This trial will help answer that question so that treatment can be better tailored to people who have COPD.
You likely qualify if…
You likely don't qualify if…
You will visit the study site three times over 10 weeks after your first visit. At each visit, you'll take one pill of the medication once per day for two weeks, then have a two-week break before starting the next dose. The pills will look identical and contain different amounts of the medication in different orders depending on which group you're randomly assigned to. At each visit, the study team will collect blood and urine samples to measure how your body is responding, and you'll complete breathing tests.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States